Inovio Non Current Assets Total vs Common Stock Shares Outstanding Analysis
| INO Stock | USD 4.07 0.01 0.25% |
Inovio Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Inovio Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Inovio Pharmaceuticals is a good investment. Please check the relationship between Inovio Pharmaceuticals Non Current Assets Total and its Common Stock Shares Outstanding accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.
Non Current Assets Total vs Common Stock Shares Outstanding
Non Current Assets Total vs Common Stock Shares Outstanding Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Inovio Pharmaceuticals Non Current Assets Total account and Common Stock Shares Outstanding. At this time, the significance of the direction appears to have very week relationship.
The correlation between Inovio Pharmaceuticals' Non Current Assets Total and Common Stock Shares Outstanding is 0.27. Overlapping area represents the amount of variation of Non Current Assets Total that can explain the historical movement of Common Stock Shares Outstanding in the same time period over historical financial statements of Inovio Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Inovio Pharmaceuticals' Non Current Assets Total and Common Stock Shares Outstanding is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Assets Total of Inovio Pharmaceuticals are associated (or correlated) with its Common Stock Shares Outstanding. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Shares Outstanding has no effect on the direction of Non Current Assets Total i.e., Inovio Pharmaceuticals' Non Current Assets Total and Common Stock Shares Outstanding go up and down completely randomly.
Correlation Coefficient | 0.27 |
| Relationship Direction | Positive |
| Relationship Strength | Very Weak |
Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Common Stock Shares Outstanding
The total number of shares of a company's common stock that are currently owned by all its shareholders.Most indicators from Inovio Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Inovio Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.At this time, Inovio Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 24th of November 2024, Sales General And Administrative To Revenue is likely to grow to 60.05, while Issuance Of Capital Stock is likely to drop about 9.8 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 1.9M | 1.3M | 1.2M | 1.2M | Depreciation And Amortization | 4.7M | 5.5M | 3.5M | 2.4M |
Inovio Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Inovio Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Inovio Pharmaceuticals fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 144.0M | 539.8M | 495.9M | 348.5M | 172.9M | 131.2M | |
| Total Current Liabilities | 32.0M | 41.7M | 65.7M | 96.9M | 42.6M | 23.4M | |
| Total Stockholder Equity | 3.4M | 461.1M | 399.7M | 222.4M | 117.3M | 95.2M | |
| Property Plant And Equipment Net | 26.6M | 24.1M | 29.0M | 18.0M | 14.5M | 7.5M | |
| Net Debt | 77.3M | (211.7M) | (38.1M) | (14.3M) | 15.9M | 16.7M | |
| Retained Earnings | (739.8M) | (906.2M) | (1.2B) | (1.5B) | (1.6B) | (1.5B) | |
| Accounts Payable | 7.6M | 1.5M | 28.0M | 21.1M | 4.6M | 5.0M | |
| Cash | 22.2M | 250.7M | 71.1M | 46.3M | 14.3M | 13.6M | |
| Non Current Assets Total | 49.8M | 68.6M | 47.5M | 33.3M | 19.8M | 28.2M | |
| Cash And Short Term Investments | 89.5M | 411.6M | 401.3M | 253.0M | 145.3M | 92.0M | |
| Net Receivables | 2.0M | 19.1M | 8.0M | 11.7M | 2.4M | 3.9M | |
| Common Stock Shares Outstanding | 8.2M | 12.9M | 17.4M | 19.9M | 22.2M | 28.0M | |
| Liabilities And Stockholders Equity | 144.0M | 539.8M | 495.9M | 348.5M | 172.9M | 131.2M | |
| Non Current Liabilities Total | 106.6M | 36.9M | 30.5M | 29.3M | 13.0M | 12.1M | |
| Other Current Assets | 2.6M | 40.5M | 39.1M | 50.5M | 5.4M | 6.9M | |
| Other Stockholder Equity | 742.6M | 1.4B | 1.6B | 1.7B | 1.7B | 1.8B | |
| Total Liab | 138.5M | 78.6M | 96.3M | 126.2M | 55.6M | 35.5M | |
| Property Plant And Equipment Gross | 26.6M | 24.1M | 48.0M | 18.0M | 35.3M | 37.1M | |
| Total Current Assets | 94.2M | 471.2M | 448.4M | 315.2M | 153.1M | 103.0M | |
| Accumulated Other Comprehensive Income | 472.6K | (256.2K) | (282.2K) | (698.7K) | (662.6K) | (629.5K) | |
| Intangible Assets | 3.7M | 3.1M | 2.6M | 2.1M | 2.4M | 2.3M | |
| Other Current Liab | 22.1M | 37.9M | 35.1M | 73.0M | 18.7M | 11.5M | |
| Other Liab | 9.1M | 206.4K | 111.2K | 32.0K | 36.9K | 35.0K | |
| Non Currrent Assets Other | (5.4M) | 22.2M | (1.5M) | (1.6M) | 605.3K | 635.6K | |
| Other Assets | 2.7M | 43.6M | 1.4M | 684.0K | 1.0 | 0.95 | |
| Common Stock Total Equity | 101.4K | 186.9K | 217.4K | 253.1K | 227.8K | 216.4K | |
| Common Stock | 101.4K | 186.9K | 217.4K | 253.1K | 22.8K | 21.7K | |
| Property Plant Equipment | 12.8M | 11.3M | 17.5M | 7.7M | 8.9M | 5.2M | |
| Current Deferred Revenue | 257.2K | 124.1K | 46.6K | 21.6K | 24.9K | 23.6K | |
| Short Term Investments | 67.3M | 160.9M | 330.2M | 206.7M | 131.0M | 85.0M | |
| Net Tangible Assets | (10.8M) | 447.5M | 386.5M | 209.7M | 241.2M | 159.6M | |
| Retained Earnings Total Equity | (739.8M) | (906.2M) | (1.2B) | (1.5B) | (1.3B) | (1.3B) | |
| Capital Surpluse | 742.6M | 1.4B | 1.6B | 1.7B | 2.0B | 2.1B |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.43) | Revenue Per Share 0.025 | Quarterly Revenue Growth (0.55) | Return On Assets (0.40) | Return On Equity (0.91) |
The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.